Mangrove Partners’s Protagonist Therapeutics PTGX Stock Holding History

Mangrove Partners’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-478,413	Closed	-$31.8M	–	424
2025 Q3	$31.8M	Buy	478,413 +83,030	+21%	+$4.72M	2.35%	17
2025 Q2	$21.9M	Hold	395,383	–	–	2.35%	16
2025 Q1	$19.1M	Hold	395,383	–	–	2.07%	17
2024 Q4	$15.3M	Sell	395,383 -43,931	-10%	-$1.92M	1.69%	22
2024 Q3	$19.8M	Hold	439,314	–	–	1.7%	22
2024 Q2	$15.2M	Hold	439,314	–	–	1.17%	29
2024 Q1	$12.7M	Hold	439,314	–	–	0.88%	35
2023 Q4	$10.1M	Hold	439,314	–	–	0.68%	46
2023 Q3	$7.33M	Buy	+439,314	New	+$8.52M	0.55%	61
2022 Q1	–	Sell	-433,137	Closed	-$14.8M	–	474
2021 Q4	$14.8M	Buy	+433,137	New	+$13.7M	0.88%	13

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mangrove Partners's PTGX Position: Q4 2025 in Review

Mangrove Partners sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 478,413 shares — an estimated $31.8M sold.

Mangrove Partners first reported a position in PTGX in Q4 2021 and held it in 10 quarters. The position peaked at $31.8M in Q3 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Mangrove Partners reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
Mangrove Partners sold 478,413 Protagonist Therapeutics shares in Q4 2025, an estimated $31.8M.
Mangrove Partners first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 10 quarters.
Mangrove Partners's Protagonist Therapeutics position peaked at $31.8M in Q3 2025.
313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Mangrove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.